Hemispherx Biopharma announced a two-prong Chronic Fatigue Syndrome, CFS- clinical mission for November and December 2009 . The company plans to widen its ongoing clinical programs in CFS by accelerating collaborations with a consortium of researchers who have just discovered a retroviral link to Chronic Fatigue Syndrome . A clinically validated test to detect retrovirus antibodies in patients plasma is also currently under development. The company also plans to complete all outstanding queries from the FDA regarding its New Drug Application -NDA- for Ampligen, an experimental therapeutic, during November and December, 2009
this piece of shit is trading @ 1.10 PM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment